3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
6
Other hematologic neoplasm
6
Gynecologic
6
Breast
6
Genitourinary
5
Gastrointestinal
5
Lymphoid
3
Head & Neck
3
Tumor-Agnostic
2
Dermatologic
2
CNS
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Conditions
Retinoblastoma
1
Interventions
pembrolizumab
27
Pemetrexed
10
Nivolumab
10
Cyclophosphamide
10
Carboplatin
10
atezolizumab
8
Specimen Handling
8
Cisplatin
8
Ipilimumab
6
Biopsy
6
fludarabine
5
Injections
5
tislelizumab
4
spartalizumab
4
Vincristine
4
Radiotherapy
4
Proton Therapy
4
Platinum
4
Paclitaxel
4
Drug Therapy
4
Docetaxel
4
Bevacizumab
4
1,2-diaminocyclohexaneplatinum II citrate
4
sintilimab
3
durvalumab
3
Trastuzumab
3
Etoposide
3
Cetuximab
3
zimberelimab
2
trametinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Observation
×
Other solid neoplasm
×
Clear all
NCT02870907
2026-01-07
RB SFCE 09
Institut Curie
Phase 2
Active not recruiting
195 enrolled